Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …

Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …

Opinion statement Relapse is still a common scenario in acute myeloid leukemia (AML)
treatment and occurs in 40–50% of younger and the great majority of elderly patients. The …

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by
immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation …

FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an
important role in hematopoietic cell survival, proliferation and differentiation. The most …